Last reviewed 2026-04-19 · How we verify

Acute myeloid leukemia, disease

Approved treatments

• Xospata · French Innovative Leukemia Organisation
• Dacogen · Sun Pharma
  Dacogen works by inhibiting the enzyme that adds methyl groups to DNA, which helps to restore normal gene function in cancer cells.
• Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
• Vidaza · Bristol-Myers Squibb
  Vidaza works by incorporating itself into DNA and interfering with the enzyme that adds methyl groups, which helps to restore normal gene function in cancer cells.
• Vanflyta · Daiichi Sankyo Inc
  Vanflyta works by blocking the macrophage colony-stimulating factor 1 receptor, which is involved in the growth and survival of cancer cells.
• Fludara · Nihon Schering K.K.
  Fludara works by interfering with the production of DNA and RNA in cancer cells, ultimately leading to cell death.
• Idamycin Pfs · Pfizer Inc.
  Idarubicin forms DNA complexes, inhibits nucleic acid synthesis and topoisomerase II, produces DNA-damaging free radicals.
• Dacogen · Mayo Clinic
• Daunorubicine · Gruppo Italiano Malattie EMatologiche dell'Adulto
• Eramin · Eli Lilly
• Mylotarg · Pfizer
  CD33-directed antibody-drug conjugate that delivers cytotoxic calicheamicin to tumor cells.
• Cytarabine · Nippon Shinyaku Co., Ltd.
  Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase.
• adriacin · Chipscreen Biosciences, Ltd.
• Hydroxydaunorubicin · University of Colorado, Denver
• Rydapt · Novartis
  Rydapt blocks the activity of the Kit receptor, which is involved in the growth and survival of cancer cells.
• aclacinomycin · Chinese PLA General Hospital
• Idhifa · Bristol-Myers Squibb
  Idhifa works by blocking the IDH2 enzyme, which is mutated in some AML cells, to prevent the production of a toxic metabolite that promotes cancer growth.
• azacytidine · Assistance Publique Hopitaux De Marseille
• Aclacur
  Aclacur works by binding to the 5-hydroxytryptamine receptor 2B, which is involved in cell growth and proliferation.
• Novantrone
  Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division.
• Thioguanine · Waylis
• Daurismo · Pfizer
  Daurismo works by blocking the Smoothened homolog, a protein involved in the Hedgehog signaling pathway, which is often dysregulated in cancer cells.
• Idamycin Pfs
  Idarubicin hydrochloride exerts its effects by forming DNA complexes, inhibiting nucleic acid synthesis, blocking topoisomerase II, and generating DNA-damaging free radicals.
• Mylotarg · Pfizer
  Mylotarg works by binding to CD33 on cancer cells and releasing a toxic compound that kills the cells.
• Venclexta · AbbVie
  Venclexta is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein.
• Daurismo · Pfizer
  Glasdegib inhibits Smoothened, a transmembrane protein in the Hedgehog signaling pathway.
• Tibsovo · Servier
  Ivosidenib inhibits mutant IDH1, reducing 2-HG levels and promoting myeloid differentiation in AML.
• Proleukin · Chiron
• Liposomal Doxorubicin · Pfizer
• Xospata · Astellas Pharma
  Xospata works by blocking the activity of a specific enzyme called Leukocyte tyrosine kinase receptor.
• Rezlidhia · Rigel Pharms
  Olutasidenib inhibits mutated IDH1, reducing 2-HG levels in AML cells.
• Doxorubicin Hydrochloride · Pfizer
  Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division.
• Idamycin Pfs
  Idarubicin works by binding to DNA topoisomerase 2-alpha, preventing the enzyme from unwinding DNA and leading to cell death.
• Fludarabin · Azienda Ospedaliera San Giovanni Battista
• Hydroxydaunomycin · Weill Medical College of Cornell University
• Proleukin · University of Minnesota
• Fludara · Celyad Oncology SA
• Adriamycin · Johann Wolfgang Goethe University Hospital
• Mitozantrone · US Department of Veterans Affairs

Clinical guidelines

• FDA label — 1L
  IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen.
• FDA label — 1L
  IDAMYCIN PFS is indicated for the treatment of adult patients with acute promyelocytic leukemia (FAB M3) as a component of a combination chemotherapy regimen.
• FDA label — 1L
  DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
• FDA label — 1L
  IDAMYCIN PFS is indicated for the treatment of adult patients with acute myeloid leukemia (AML) as a component of a combination chemotherapy regimen.
• FDA label — 1L
  IDAMYCIN PFS is indicated for the treatment of adult patients with acute promyelocytic leukemia (FAB M3) as a component of a combination chemotherapy regimen.
• FDA label — 1L
  VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
• FDA label — 1L
  DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Acute myeloid leukemia, disease patent landscape — cliff calendar, originator estates, attackable patents
• Acute myeloid leukemia, disease treatment landscape brief
• Acute myeloid leukemia, disease treatment updates RSS

Frequently asked questions about Acute myeloid leukemia, disease

Related

• Treatment landscape: Acute myeloid leukemia, disease patent cliff · Acute myeloid leukemia, disease CI report
• Treatment: Xospata · French Innovative Leukemia Organisation
• Treatment: Dacogen · Sun Pharma
• Treatment: Daunorubicin Hydrochloride · Meiji Seika Pharma Co., Ltd
• Treatment: Vidaza · Bristol-Myers Squibb
• Treatment: Vanflyta · Daiichi Sankyo Inc
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing